Department of Pain Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, Henan, P. R. China.
Department of Human Anatomy, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, Henan, P. R. China.
ACS Nano. 2024 Jul 2;18(26):16450-16467. doi: 10.1021/acsnano.4c03425. Epub 2024 Jun 19.
Nanozymes, which can selectively scavenge reactive oxygen species (ROS), have recently emerged as promising candidates for treating ischemic stroke and traumatic brain injury (TBI) in preclinical models. ROS overproduction during the early phase of these diseases leads to oxidative brain damage, which has been a major cause of mortality worldwide. However, the clinical application of ROS-scavenging enzymes is limited by their short in vivo half-life and inability to cross the blood-brain barrier. Nanozymes, which mimic the catalytic function of natural enzymes, have several advantages, including cost-effectiveness, high stability, and easy storage. These advantages render them superior to natural enzymes for disease diagnosis and therapeutic interventions. This review highlights recent advancements in nanozyme applications for ischemic stroke and TBI, emphasizing their potential to mitigate the detrimental effect of ROS overproduction, oxidative brain damage, inflammation, and blood-brain barrier compromise. Therefore, nanozymes represent a promising treatment modality for ROS overproduction conditions in future medical practices.
纳米酶可以选择性地清除活性氧（ROS），最近在缺血性脑卒中及创伤性脑损伤（TBI）的临床前模型中成为一种很有前途的治疗候选物。这些疾病早期阶段的 ROS 过度产生会导致氧化脑损伤，这是全球范围内主要的死亡原因。然而，ROS 清除酶的临床应用受到其体内半衰期短和不能穿过血脑屏障的限制。纳米酶模拟天然酶的催化功能，具有成本效益高、稳定性高、易于储存等优点。这些优点使它们在疾病诊断和治疗干预方面优于天然酶。这篇综述强调了纳米酶在缺血性脑卒中及 TBI 中的应用的最新进展，突出了它们在减轻 ROS 过度产生、氧化脑损伤、炎症和血脑屏障损伤的有害影响方面的潜力。因此，纳米酶代表了未来医学实践中治疗 ROS 过度产生疾病的一种有前途的治疗方式。
